Switch theme
Sign up to access all valuation multiples
Innovita Biological Technology Co Ltd is a biotechnology company focusing on the research and development, production and sales of POCT in vitro diagnostic products.
2006
n/a
LTM Revenue $90.2M
LTM EBITDA $40.0M
$346M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Innovita Biological Tech has a last 12-month revenue (LTM) of $90.2M and a last 12-month EBITDA of $40.0M.
In the most recent fiscal year, Innovita Biological Tech achieved revenue of $86.2M and an EBITDA of $41.4M.
Innovita Biological Tech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Innovita Biological Tech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $90.2M | XXX | $86.2M | XXX | XXX | XXX |
| Gross Profit | $73.0M | XXX | $69.1M | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | $40.0M | XXX | $41.4M | XXX | XXX | XXX |
| EBITDA Margin | 44% | XXX | 48% | XXX | XXX | XXX |
| EBIT | $39.9M | XXX | $34.6M | XXX | XXX | XXX |
| EBIT Margin | 44% | XXX | 40% | XXX | XXX | XXX |
| Net Profit | $35.6M | XXX | $34.3M | XXX | XXX | XXX |
| Net Margin | 40% | XXX | 40% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Innovita Biological Tech's stock price is CNY 33 (or $5).
Innovita Biological Tech has current market cap of CNY 4.5B (or $619M), and EV of CNY 2.5B (or $346M).
See Innovita Biological Tech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $346M | $619M | XXX | XXX | XXX | XXX | $0.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Innovita Biological Tech has market cap of $619M and EV of $346M.
Innovita Biological Tech's trades at 4.0x EV/Revenue multiple, and 8.3x EV/EBITDA.
Equity research analysts estimate Innovita Biological Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Innovita Biological Tech has a P/E ratio of 17.4x.
See valuation multiples for Innovita Biological Tech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $619M | XXX | $619M | XXX | XXX | XXX |
| EV (current) | $346M | XXX | $346M | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 8.6x | XXX | 8.3x | XXX | XXX | XXX |
| EV/EBIT | 8.7x | XXX | 10.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 17.4x | XXX | 18.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 9.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInnovita Biological Tech's last 12 month revenue growth is 13%
Innovita Biological Tech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Innovita Biological Tech's rule of 40 is 59% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Innovita Biological Tech's rule of X is 76% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Innovita Biological Tech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 44% | XXX | 48% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 59% | XXX | 61% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 76% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Innovita Biological Tech acquired XXX companies to date.
Last acquisition by Innovita Biological Tech was XXXXXXXX, XXXXX XXXXX XXXXXX . Innovita Biological Tech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Innovita Biological Tech founded? | Innovita Biological Tech was founded in 2006. |
| Where is Innovita Biological Tech headquartered? | Innovita Biological Tech is headquartered in China. |
| Is Innovita Biological Tech publicy listed? | Yes, Innovita Biological Tech is a public company listed on SHG. |
| What is the stock symbol of Innovita Biological Tech? | Innovita Biological Tech trades under 688253 ticker. |
| When did Innovita Biological Tech go public? | Innovita Biological Tech went public in 2022. |
| Who are competitors of Innovita Biological Tech? | Similar companies to Innovita Biological Tech include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Innovita Biological Tech? | Innovita Biological Tech's current market cap is $619M |
| What is the current revenue of Innovita Biological Tech? | Innovita Biological Tech's last 12 months revenue is $90.2M. |
| What is the current revenue growth of Innovita Biological Tech? | Innovita Biological Tech revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Innovita Biological Tech? | Current revenue multiple of Innovita Biological Tech is 3.8x. |
| Is Innovita Biological Tech profitable? | Yes, Innovita Biological Tech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Innovita Biological Tech? | Innovita Biological Tech's last 12 months EBITDA is $40.0M. |
| What is Innovita Biological Tech's EBITDA margin? | Innovita Biological Tech's last 12 months EBITDA margin is 44%. |
| What is the current EV/EBITDA multiple of Innovita Biological Tech? | Current EBITDA multiple of Innovita Biological Tech is 8.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
